Novo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek®
View original at finance.yahoo.comNovo Nordisk's CagriSema was associated with significant reduction in blood pressure and showed anti-inflammatory effects while reducing the proportion of patients at risk of developing heart disease over time in new analyses at ObesityWeek® A post hoc analysis of REDEFINE 1 demonstrated a 10.9 mmHg reduction in systol…
Ce que nous avons tiré de cette source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Semaglutide 2.4 mg reduced systolic blood pressure by 8.8 mmHg over 68 weeks
80% confidenceOverall discontinuation rates due to adverse events were low, with 6% for CagriSema versus 3.7% for placebo
80% confidenceObesity is a chronic relapsing progressive disease process
80% confidenceThe reduction in hsCRP with CagriSema (68.9%) was greater than with semaglutide 2.4 mg alone (55.4%) or placebo (16.0%)
80% confidenceFewer people on CagriSema were at intermediate-to-high risk of developing atherosclerotic cardiovascular disease within the next 10 years
80% confidenceThe hsCRP reduction with CagriSema was only partially explained by weight loss, suggesting that the inflammatory effects are not fully weight loss dependent
80% confidencePlacebo reduced systolic blood pressure by 2.1 mmHg over 68 weeks
80% confidenceCagriSema (2.4 mg/2.4 mg) demonstrated a 10.9 mmHg reduction in systolic blood pressure over 68 weeks
80% confidenceThe CagriSema data are very encouraging regarding the effects on well-known CV risk factors like high blood pressure
80% confidence40% of people on blood pressure medications were able to reduce or stop their medication with CagriSema treatment
80% confidencePeople living with obesity have treatment goals that often include both losing weight and improving overall health
80% confidenceAdverse events in REDEFINE 1 were mainly gastrointestinal (79.6% in the CagriSema group versus 39.9% with placebo) and were mostly transient and mild-to-moderate in severity
80% confidenceCagriSema treatment demonstrated a nearly 70% reduction in hsCRP, a key inflammatory marker associated with increased cardiovascular risk
80% confidence
Data points we hold from this source
| Novo Nordisk · markets served | 170 countries |
| Novo Nordisk · us employee count | 10000 employees |
| Novo Nordisk · employee count | 78500 employees |